Does Sentinel Lymph Node Biopsy Accurately Stage the Clinically Negative Neck in Early Oral Cavity Squamous Cell Carcinoma?


Journal

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
ISSN: 1531-5053
Titre abrégé: J Oral Maxillofac Surg
Pays: United States
ID NLM: 8206428

Informations de publication

Date de publication:
06 2022
Historique:
received: 31 08 2021
revised: 13 02 2022
accepted: 14 02 2022
pubmed: 20 3 2022
medline: 9 6 2022
entrez: 19 3 2022
Statut: ppublish

Résumé

Sentinel lymph node biopsy (SLNB) is being increasingly used worldwide as a minimally invasive option to stage the clinically node-negative neck (N0) in patients with early oral cavity squamous cell carcinomas (OCSCC). We performed this trial to assess the reliability and validity of the technique. We did this prospective interventional nonrandomized study in patients with early (cT1-T2 OCSCC) and with negative neck. All patients underwent preoperative lymphoscintigraphy; SLNB was followed immediately by completion neck dissection (CND), thus each patient serving as their own control. The primary outcomes evaluated are sentinel lymph node (SLN) detection rate, SLN retrieval rate, and SLN status (positive or negative) compared with pathology of CND specimen to detect any false negatives. The secondary outcomes included SLN analyses (tumor burden, location in different levels of the neck, laterality, extracapsular spread, and total nodes positive) and overall survival. Of 60 patients, 59 (98%) had successful SLN detection with the lymphoscintigram failing to localize in 1 patient. Of the remaining 59 patients, 58 (96%) had all the SLNs retrieved, resulting in 96.4% sentinel node retrieval rate. In total, 24 (41%) SLNs were positive with 1 false negative. Using a combination of SLN and CND findings as the gold standard for lymph node involvement status, SLNB had a sensitivity of 96% (95% confidence interval [CI]: 80-100%), a specificity of 100% (95% CI: 90-100%), and negative predictive value of 97% (95% CI: 85-100%). The results of this study suggest that SLNB is an accurate technique to assess the nodal status in patients with cT1-T2 N0 OCSCC and should be considered for eligible patients.

Identifiants

pubmed: 35304106
pii: S0278-2391(22)00146-X
doi: 10.1016/j.joms.2022.02.006
pii:
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1134-1142

Informations de copyright

Crown Copyright © 2022. Published by Elsevier Inc. All rights reserved.

Auteurs

Muzib Abdul-Razak (M)

Senior Staff Specialist, Head and Neck Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia; Senior Staff Specialist, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia. Electronic address: razaksurg@gmail.com.

Derek Mwagiru (D)

Surgical Registrar, Head and Neck Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.

Michael Veness (M)

Professor, Senior Staff Specialist, Head and Neck Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia; Professor, Senior Staff Specialist, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Eva Wong (E)

Staff Specialist, Head and Neck Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia; Staff Specialist, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Tony Pang (T)

Professor, Surgical Innovations Unit, Westmead Hospital, Sydney, New South Wales, Australia.

Gary Morgan (G)

Associate Professor, Head and Neck Cancer Service, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia; Associate Professor, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH